Actively Recruiting
Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-12-04
48
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the safety and efficacy of LILRA6-directed chimeric antigen receptor T cells (LILRA6 CAR-T cells) in patients with refractory or relapsed acute myeloid leukemia(AML).
CONDITIONS
Official Title
Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agree to participate and sign informed consent
- Age between 18 and 75 years
- Diagnosis of refractory or recurrent AML meeting specific disease criteria
- Expected survival of at least 12 weeks
- LILRA6 expression in bone marrow or tumor cells of 20% or more
- ECOG performance status score of 0 to 2
- Adequate organ function including liver enzymes, kidney function, heart ejection fraction, oxygen saturation, and blood counts
- Previous single autologous hematopoietic stem cell transplantation allowed
- Negative pregnancy test for women of childbearing age and agreement to use contraception during the trial
- No uncontrolled infections including lung infections
- At least 3 weeks since last systemic chemotherapy, radiotherapy, or immunotherapy; at least 2 weeks since targeted drug treatment
- No active COVID-19 or influenza infection
You will not qualify if you...
- History of severe allergic reaction to cell preparation components or pre-treatment chemotherapy drugs
- History of other active cancers
- Active infections requiring treatment (except simple urinary tract infections or bacterial pharyngitis)
- Active hepatitis B, hepatitis C, syphilis, or immune deficiency disorders including HIV
- Severe heart dysfunction (NYHA class III or IV)
- Unrecovered toxic reactions from previous anti-tumor treatments except fatigue, appetite loss, or hair loss
- History of epilepsy or other central nervous system diseases affecting assessment
- Previous treatment with targeted LILRA6 drugs
- Breastfeeding women unwilling to stop breastfeeding
- Any other conditions deemed by researchers to increase risk or interfere with study results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital,School of Medicine,Zhejiang University
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
W
Wenbin Qian, Professor
CONTACT
W
Wen Lei, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here